676 Results

People

  1. Robson
    Robson
  2. Offit
    Offit
  3. Stadler
    Stadler
  4. Joseph
    Joseph
  5. Mandelker
    Mandelker
  6. Berger
    Berger
  7. Solit
    Solit
  8. Hudis
    Hudis
  9. Kauff
    Kauff
  10. Kemel
    Kemel

Groups

  1. Breast Medicine Service (676)
  2. Department of Medicine (676)
  3. Population Sciences Research Program (676)
  4. Solid Tumor Oncology Division (676)
  5. Survivorship Research (676)
  6. GSK Faculty (376)
  7. Clinical Genetics Service (297)
  8. Surgery (188)
  9. Department of Pathology and Laboratory Medicine (187)
  10. Epidemiology and Biostatistics (185)
  1. "Mark Robson"
Formats
  1. Journal Article (382)
  2. Meeting Abstract (259)
  3. Review (10)
  4. Book Section (7)
  5. Editorial (6)
  6. Guidelines (6)
  7. Miscellaneous (4)
  8. Correspondence (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (676)
  2. Department of Medicine (676)
  3. Population Sciences Research Program (676)
  4. Solid Tumor Oncology Division (676)
  5. Survivorship Research (676)
  6. GSK Faculty (376)

More Groups

People
  1. Mark Robson (676)
  2. Kenneth Offit (280)
  3. Zsofia Stadler (116)
  4. Larry Norton (89)
  5. Vijai Joseph (79)
  6. Diana Mandelker (74)

More People

Years
  1. 2025 (2)
  2. 2024 (32)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (46)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (163)
  2. Cancer Research (50)
  3. Breast Cancer Research and Treatment (33)
  4. JNCI: Journal of the National Cancer Institute (20)
  5. Annals of Oncology (18)
  6. Clinical Cancer Research (17)

More Publications

Publishers
  1. American Society of Clinical Oncology (185)
  2. American Association for Cancer Research (82)
  3. Springer (66)
  4. Nature Publishing Group (60)
  5. Elsevier Inc. (50)
  6. Oxford University Press (42)

More Publishers

Results (676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants and risk of contralateral breast cancer
    Journal Article

    Reiner, A. S.; Robson, M. E.; Mellemkjær, L.; Tischkowitz, M.; John, E. M.; Lynch, C. F.; Brooks, J. D.; Boice, J. D.; Knight, J. A.; Teraoka, S. N.; more...
    JNCI: Journal of the National Cancer Institute (2020)

    Fulltext@MSK | Save
  • Yoga for chemotherapy-induced peripheral neuropathy and fall risk: A randomized controlled trial
    Journal Article

    Bao, T.; Zhi, I.; Baser, R.; Hooper, M.; Chen, C.; Piulson, L.; Li, Q. S.; Galantino, M. L.; Blinder, V.; Robson, M.; more...
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save
  • KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
    Meeting Abstract

    Saji, S.; Llombart Cussac, A.; Andre, F.; Robson, M. E.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; Fan, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D
    Journal Article

    Yang, X.; Song, H.; Leslie, G.; Engel, C.; Hahnen, E.; Auber, B.; Horváth, J.; Kast, K.; Niederacher, D.; Turnbull, C.; more...
    JNCI: Journal of the National Cancer Institute (2020)

    Fulltext@MSK | Save
  • TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
    Journal Article

    Tung, N. M.; Robson, M. E.; Ventz, S.; Santa-Maria, C. A.; Nanda, R.; Marcom, P. K.; Shah, P. D.; Ballinger, T. J.; Yang, E. S.; Vinayak, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis
    Journal Article

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Kelly, D.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; more...
    Nature Genetics (2020)

    Fulltext@MSK | Save
  • TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)
    Meeting Abstract

    Tung, N. M.; Robson, M. E.; Ventz, S.; Santa-Maria, C. A.; Marcom, P. K.; Nanda, R.; Shah, P. D.; Ballinger, T. J.; Yang, E. S. H.; Melisko, M. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and clinical characterization of MMR-D/MSI extra-colonic cancers among germline PMS2 mutation carriers
    Meeting Abstract

    Latham, A.; Salo-Mullen, E. E.; Catchings, A.; Ranganathan, M.; Fiala, E.; Kemel, Y.; Konner, J. A.; Soslow, R. A.; Momeni-Boroujeni, A.; Shia, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Genetic testing experiences and emotional reactions among individuals with variant of uncertain significance results from cancer multiplex genetic testing
    Meeting Abstract

    Hamilton, J. G.; Brower, J.; Clark, D.; Ebrahimzadeh, J. E.; Kane, S. R.; Sanchez, P.; Wildman, T.; Merrill, M.; Couch, F.; Garber, J. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save